记者丨易妍君 编辑丨张星 2026年，A股旗开得胜，三大股指在首个交易日（即1月5日）悉数上涨。 这一天，上证指数重返4000点之上，日线更是迎来罕见的12连阳，为"春季躁动"预期下的A股市场再添"一把火"。 市场热点轮番活跃，脑机接口、保险、存储器等题材相对强势；CRO、模拟芯片、基因检测、虚拟人等概念也有不错的表现。 展望后市，前海开源基金首席经济学家、基金经理杨德龙判断，2026年科技牛行情有望延续。 多因素助推A股"开门红" 1月5日，A股市场高开高走，喜迎2026年"开门红"。 截至当日收盘，上证指数涨1.38%，报4023.42点；深证成指涨2.24%，报13828.63点；创业板指的涨幅接近2.9%，报3294.55点。科 创50指数则大涨4.41%，北证50指数上涨1.8%。 当天，全部A股成交额达2.57万亿元，较前一个交易日增加了5000多亿元。全市场近4200只个股上涨。 在业内人士看来，A股"开门红"得益于多重积极因素的共振。 "节后市场情绪在假期港股走强的带动下显著回暖； 资金层面，市场对年内保险资金等长期增量资金入市抱有期待，同时全球流动 性宽松预期也提振了风险偏好；更深层次的驱动 ...

Investment Rating - The report maintains a "Positive" investment rating for the healthcare sector [10]. Core Insights - Elon Musk announced on December 31, 2025, that his brain-computer interface company Neuralink will begin "mass production" of brain-computer interface devices in 2026, transitioning to a "more streamlined and almost fully automated surgical process" [2][6]. - The brain-computer interface market has significant growth potential, with invasive products expected to become a key focus area. Internationally, companies like Neuralink are leading in technology, while several domestic companies in China have made breakthroughs in R&D, supported by favorable policies [2]. - The global brain-computer interface market is projected to reach USD 2.62 billion by 2024, with a compound annual growth rate (CAGR) of 17.4% from 2025 to 2034. In China, the market is expected to exceed RMB 6 billion by 2028, with a CAGR of approximately 17.7% from 2024 to 2028 [14]. - Neuralink employs a minimally invasive implantation approach, with 12 individuals having implanted devices as of September 2025, totaling over 20,000 hours of usage [14]. - Several domestic companies have achieved breakthroughs in brain-computer interface technology, with notable advancements in clinical trials and regulatory approvals [14]. - The industry is encouraged by supportive policies, with the National Healthcare Security Administration in China having established pricing for brain-computer interface services [14]. - Experimental animals, such as mice and monkeys, play a crucial role in brain-computer interface research, with mice being used for initial testing and monkeys for more advanced validation due to their closer anatomical and functional similarities to humans [14]. - Recommended companies to watch include Meihao Medical for brain-computer interfaces and Zhaoyan New Drug for experimental animals [14].

Core Viewpoint - The A-share market started 2026 on a positive note, with all three major indices rising, indicating a shift from valuation recovery in 2025 to profit-driven growth in 2026 [1][5]. Market Performance - On January 5, 2026, the Shanghai Composite Index rose by 1.38% to 4023.42 points, the Shenzhen Component Index increased by 2.24% to 13828.63 points, and the ChiNext Index saw a rise of nearly 2.9% to 3294.55 points [5]. - The total trading volume reached 2.57 trillion yuan, an increase of over 500 billion yuan compared to the previous trading day, with nearly 4200 stocks rising [5]. Sector Highlights - Key sectors showing strong performance included brain-computer interfaces, insurance, and storage devices, with significant gains in AI applications and emerging industries [2][6]. - The brain-computer interface sector experienced a surge, with related stocks hitting the daily limit, driven by news from overseas about Neuralink's plans for large-scale production [7][9]. Investment Outlook - Analysts predict that the 2026 technology bull market is likely to continue, with a focus on sectors such as technology growth, advanced manufacturing, and cyclical consumption [2][12]. - Investment strategies for 2026 include a balanced approach of high-quality stocks and high-potential sectors, emphasizing technology companies with strong fundamentals and emerging industries [13]. Structural Opportunities - The pharmaceutical sector is expected to see structural opportunities driven by innovation, international expansion, and policy reforms, with a focus on innovative drugs and AI integration in healthcare [14].

Group 1: Market Overview - The international oil market is experiencing volatility due to uncertainty surrounding Venezuela's oil reserves, with WTI crude oil rising by 1.64% to $58.15 per barrel and Brent crude oil increasing by 1.61% to $61.71 per barrel [4] - Major European stock indices closed higher, with the UK FTSE 100 up by 0.54%, Germany's DAX up by 1.34%, and the Euro Stoxx 50 up by 1.25% [4] - US stock indices also saw gains, with the Dow Jones rising by 1.23% to a new high, the S&P 500 up by 0.64%, and the Nasdaq up by 0.69% [4] Group 2: Commodity Performance - Spot gold increased by 2.74% to $4,449.04 per ounce, while spot silver rose by 5.42% to $76.6 per ounce [7] - LME copper prices surged to $13,000 for the first time [3] - The performance of precious metals is attributed to increased safe-haven demand amid the situation in Venezuela [3] Group 3: Specific Company Movements - Chevron (CVX.N) shares rose by 5.2%, nearing a new high, while Tesla (TSLA.O) increased by 3% [4] - In the Hong Kong market, Kuaishou (01024.HK) surged over 11%, and Bilibili (09626.HK) rose over 5% [5] - In the A-share market, insurance stocks performed strongly, with New China Life Insurance rising over 8% to reach a historical high [6]

Market Performance - The A-share market experienced a strong opening on January 5, 2026, with all three major indices rising, and the Shanghai Composite Index achieving a "twelve consecutive days" increase, surpassing 4020 points [1][2] - The total market capitalization of the A-share market exceeded 120 trillion yuan, setting a historical high, with a trading volume of 2.57 trillion yuan on the same day [1][7] - Over 4100 stocks in the A-share market rose, with more than 120 stocks hitting the daily limit [1][2] Sector Performance - The brain-computer interface sector saw significant gains, with stocks like Sainuo Medical and Meihao Medical reaching a 20% limit up, and Hanwei Technology rising over 18% [3] - Other strong-performing sectors included memory, insurance, CRO, and virtual humans, with the media, pharmaceutical, and electronics industries leading the gains [2][3] - The A-share market's trading volume increased by 501.5 billion yuan compared to the previous trading day, indicating a notable increase in market activity [2] Fund Flow and Sentiment - As of December 2025, the A-share market's financing balance increased by over 670 billion yuan, with more than 2300 stocks receiving net inflows from main funds on January 5, 2026 [4][5] - The financing balance for the A-share market reached a historical high of 25.41 trillion yuan by the end of December 2025 [4] - On January 5, 2026, the main funds saw a net outflow of 62.98 billion yuan, but the number of stocks with net inflows reached a new high in over a month [5][6] Investment Outlook - Analysts suggest that the spring market is expected to focus on consumption and growth as the two main themes, driven by optimistic market sentiment and expectations of policy support [1][8] - Investment strategies should prioritize high-quality technology companies with strong performance certainty and long-term growth logic, while also considering high-potential sectors like non-bank finance and AI hardware [8]

Core Viewpoint - The A-share market experienced a strong start in 2026, with all major indices rising and the total market capitalization surpassing 120 trillion yuan, marking a historical high [1][6]. Market Performance - On January 5, the Shanghai Composite Index, Shenzhen Component Index, ChiNext Index, and other indices saw increases of 1.38%, 2.24%, 2.85%, and 3.61% respectively, with the Shanghai Composite Index surpassing 4020 points [1][2]. - A total of 4185 stocks rose, with 127 hitting the daily limit, while 1168 stocks declined [2]. - The A-share market's trading volume reached 2.57 trillion yuan, an increase of 501.5 billion yuan from the previous trading day [2]. Sector Performance - The brain-computer interface sector saw significant gains, with companies like Sainuo Medical and Meihao Medical hitting the daily limit of 20% [2]. - Other strong-performing sectors included media, pharmaceuticals, and electronics, with respective increases of 4.12%, 3.85%, and 3.69% [2]. - The non-bank financial sector also rose over 3%, while sectors like oil and gas, banking, and transportation saw slight declines [2]. Funding and Investment Trends - The A-share market's financing balance increased by over 600 billion yuan in December 2025, with a notable rise in net inflows into over 2300 stocks on January 5 [1][3]. - As of December 31, 2025, the A-share margin trading balance reached 25.41 trillion yuan, marking a historical high [4]. - The electronic, defense, and machinery sectors saw significant net buying, while the computer and pharmaceutical sectors experienced net selling [4]. Optimism in Market Sentiment - Analysts noted a shift towards optimistic funding sentiment, with a continuous rise in the Shanghai Composite Index since mid-December 2025 [3][6]. - The market is expected to benefit from long-term capital inflows, particularly from insurance funds, and a favorable global liquidity environment [6][7]. - The upcoming spring market is anticipated to focus on consumption and growth as key themes [6][7].

截至1月5日收盘，上证指数报4023.42点，上涨1.38%；深证成指报13828.63点，上涨2.24%；创业板指 报3294.55点，上涨2.85%；北证50指数报1466.42点，上涨1.80%；科创综指报1695.84点，上涨3.61%。 量能方面，市场交投热情高涨，资金入场意愿强烈。沪深北三市合计成交额达2.57万亿元，较前一个交 易日放量超5000亿元。个股表现上，呈现普涨态势，超4100只个股飘红，其中超120只个股收获涨停。 脑机接口概念掀涨停潮 1月5日，市场热点主线清晰，多个赛道轮番发力。脑机接口概念成为当日最亮眼的主线，脑机接口主题 指数上涨超10%，板块掀起涨停潮，倍益康、三博脑科、美好医疗等近30只相关个股集体封板。 消息面上，埃隆·马斯克2025年12月31日在社交媒体上表示，其脑机接口公司"神经连接"（Neuralink） 将于2026年开始对脑机接口设备进行"大规模生产"，并转向"更加精简和几乎完全自动化的外科手术流 程"。 ◎记者 徐蔚 2026年首个交易日，A股市场迎来开门红，主要股指高开高走，上证指数时隔34个交易日重返4000点， 并走出12连阳，创1992年3月以来连 ...

专家脑机接口商业落地近况分享 20260105 摘要 中国将脑机接口技术纳入"十五"规划六大方向之一，并出台多项政策 和专项计划，上海市企业可申请 1,000 万至 2000 万资金支持，医保局 已将相关费用纳入立项指南，并在多省出台费用标准，政策支持力度大。 Neuralink 已完成 20 例人体实验，并计划加速临床试验，其运动皮层 解码、视觉皮层刺激和语言编码等项目进展显著，对医疗器械公司估值 产生积极影响，临床节奏的推进可能带来估值翻倍。 国内阶梯医疗估值约 15 亿美元，专注于瘫痪患者设备植入；博睿康采 用人工智能耳蜗方案，预计 2024 年底完成多中心临床试验，有望率先 获得医疗器械注册证，估值约 40 亿元人民币。 复旦大学张傅明教授团队在脑机接口康复训练方面取得进展，并申请了 美国 FDA 突破性设备认定，国内企业出海需求强烈，瘫痪患者对独立行 走能力有迫切需求。 国内电极技术与国外存在差距，国内企业可生产相关材料，但在微丝电 极集成度方面仍有提升空间；芯片方面，国内中芯国际具备生产医疗芯 片的能力，已有企业开发出 200 多通道的放大器芯片。 Q&A 当前国内外脑机接口行业的发展情况如何？ ...

产业端催化不断，脑机接口正当时 20260105 摘要 全球脑机接口市场规模在 2024 年已达 26.2 亿美元，预计 2025 至 2034 年复合增长率为 17.4%；中国市场规模相对较小，预计 2028 年 后突破 60 亿美元，增长潜力巨大。 Neuralink 公司在侵入式脑机接口领域取得进展，N1 芯片拥有 1,024 个电极信号采集点，计划提升至 3,000 个以上，并采用手术机器人进行 精确植入，但长期材料安全性仍是挑战。 非侵入式脑机接口技术门槛较低，多家公司已获二类医疗器械证书并商 业化销售，主要应用于医院康复科等，收费标准提升至 900 多元，已有 8 省份出台收费目录，增加医院收入并提高康复效率。 国家政策高度重视脑机接口行业，纳入"十五五"规划并成立专项基金， 医保局单独立项收费报销，创新审评绿色通道加速临床试验，有望在未 来几年实现更多人体临床试验和商业化。 国内脑机接口技术在电极数量上已基本对标国际水平，供应链以国内为 主，关键节点包括政策落地、一级公司进入临床试验、持续融资及上市， 非侵入式产品预计 2026 年商业化，侵入式产品有望在临床试验中取得 进展。 Q&A 脑机接口 ...

脑机接口产业最新动态电话会议 20260105 摘要 中国脑机接口产业在政策支持下快速发展，国家设立专项基金，从 2024 年的 30 亿元增至 2025 年的 700 亿元，并有多部门联合发文支 持，为产业从 0 到 1 的突破提供保障，投资者应关注受益于政策的企业。 脑机接口技术应用广泛，涵盖医疗健康、消费电子和娱乐互动等领域。 医疗健康是短期核心应用方向，包括精神疾病治疗等，而消费电子如情 绪监测耳机和娱乐互动等 C 端应用场景潜力巨大。 市场对脑机接口行业的定价逻辑已转变为注重新质生产力核心资产的战 略性站位，愿意为具备广阔护城河及高技术壁垒的远期行业支付较高估 值溢价，不再仅关注短期 EPS。 脑机接口产业链包括上游（芯片、采集设备）、中游（软硬件转化）和 下游（医疗、娱乐）。投资者应关注具备核心技术能力的公司，特别是 电极材料、芯片、算法和行业应用整合能力。 不同类型的脑机接口产品处于不同发展阶段，非侵入式产品已实现小规 模商业化，而半侵入式、侵入式产品仍处于临床试验阶段，投资者应重 点考虑不同类型产品之间的壁垒差异。 Q&A 脑机接口技术目前在全球范围内的发展状况如何？ 脑机接口技术近年来取得了 ...